These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31648434)

  • 1. Cancer patients with neutropenic septic shock: etiology and antimicrobial resistance.
    Jung SM; Kim YJ; Ryoo SM; Sohn CH; Seo DW; Lim KS; Kim WY
    Korean J Intern Med; 2020 Jul; 35(4):979-987. PubMed ID: 31648434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial E coli bacteremia in adult patients with hematological disease: A monocenter retrospective study in China.
    Ma J; Li N; Liu Y; Wang C; Liu X; Chen S; Xie X; Gan S; Wang M; Cao W; Wang F; Liu Y; Wan D; Sun L; Sun H
    Medicine (Baltimore); 2017 May; 96(21):e6959. PubMed ID: 28538389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adequacy of empiric gram-negative coverage for septic patients at an academic medical center.
    Vaughan D; Pakyz A; Stevens M; Lee K; Bernard S
    Am J Infect Control; 2019 Oct; 47(10):1194-1199. PubMed ID: 31109743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
    Nguyen AD; Heil EL; Patel NK; Duffy A; Gilmore S
    J Oncol Pharm Pract; 2016 Apr; 22(2):303-7. PubMed ID: 25567517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
    Ghosh S; Chakraborty M; Samanta S; Sinha N; Saha S; Chattopadhyay A; Roy SS; Bhattacharyya M
    Ann Hematol; 2021 Feb; 100(2):395-403. PubMed ID: 33140134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia.
    Kim YJ; Jung SM; Kang J; Ryoo SM; Sohn CH; Seo DW; Lim KS; Huh JW; Kim SH; Kim WY
    Intern Emerg Med; 2019 Apr; 14(3):433-440. PubMed ID: 30600529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
    Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
    BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols.
    Greenberg D; Moser A; Yagupsky P; Peled N; Hofman Y; Kapelushnik J; Leibovitz E
    Int J Antimicrob Agents; 2005 Jun; 25(6):469-73. PubMed ID: 15890499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating vancomycin and piperacillin-tazobactam in ED patients with severe sepsis and septic shock.
    Le C; Chu F; Dunlay R; Villar J; Fedullo P; Wardi G
    Am J Emerg Med; 2018 Aug; 36(8):1380-1385. PubMed ID: 29321120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
    Metan G; Kaynar L; Yozgat N; Elmali F; Kürkçüoglu CA; Alp E; Çetin M
    Infez Med; 2017 Mar; 25(1):33-37. PubMed ID: 28353453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empiric aztreonam is associated with increased mortality compared to beta-lactams in septic shock.
    Jaffa RK; Hammer J; Medaris LA; Anderson WE; Heffner AC; Pillinger KE
    Am J Emerg Med; 2021 Oct; 48():255-260. PubMed ID: 34004470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock.
    Pop-Vicas A; Opal SM
    Virulence; 2014 Jan; 5(1):206-12. PubMed ID: 24200870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of systemic bacterial infections during febrile neutropenia in pediatric oncology patients in tertiary care pediatric center.
    Siddaiahgari S; Manikyam A; Kumar KA; Rauthan A; Ayyar R
    Indian J Cancer; 2014; 51(4):403-5. PubMed ID: 26842136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
    Bucaneve G; Micozzi A; Picardi M; Ballanti S; Cascavilla N; Salutari P; Specchia G; Fanci R; Luppi M; Cudillo L; Cantaffa R; Milone G; Bocchia M; Martinelli G; Offidani M; Chierichini A; Fabbiano F; Quarta G; Primon V; Martino B; Manna A; Zuffa E; Ferrari A; Gentile G; Foà R; Del Favero A
    J Clin Oncol; 2014 May; 32(14):1463-71. PubMed ID: 24733807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bloodstream infections in febrile neutropenic patients: bacterial spectrum and antimicrobial susceptibility pattern.
    Butt T; Afzal RK; Ahmad RN; Salman M; Mahmood A; Anwar M
    J Ayub Med Coll Abbottabad; 2004; 16(1):18-22. PubMed ID: 15125174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
    Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.